Compare Stocks: ADXS

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXS Ayala Pharmaceuticals	$0.57 -12.3%	$0.72	$0.50 ▼ $1.95	$6.13M	1.62	21,878 shs	9,468 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXS Ayala Pharmaceuticals	+7.40%	+5.82%	+8.05%	+7.48%	-47.94%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXS Ayala Pharmaceuticals	2.00	Hold	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXS Ayala Pharmaceuticals	$10K	612.75	N/A	N/A	($0.61) per share	-0.93

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXS Ayala Pharmaceuticals	N/A	-$7.98	N/A	∞	N/A	N/A	-2,798.92%	-195.41%	5/21/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXS Ayala Pharmaceuticals	N/A	0.53	0.53

Ownership

Institutional Ownership

Company	Institutional Ownership
ADXS Ayala Pharmaceuticals	7.18%

Insider Ownership

Company	Insider Ownership
ADXS Ayala Pharmaceuticals	0.63%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXS Ayala Pharmaceuticals	N/A	10.75 million	10.68 million	Not Optionable

ADXS Headlines

Source	Headline
	StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) americanbankingnews.com - April 16 at 2:16 AM
	Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com americanbankingnews.com - April 8 at 2:20 AM
	Immunome: An Oncology Powerhouse In The Making seekingalpha.com - April 2 at 7:30 PM
	Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome globenewswire.com - March 26 at 8:00 AM
	IMNM Oct 2024 22.500 call finance.yahoo.com - March 16 at 9:25 AM
	IMNM Oct 2024 25.000 call finance.yahoo.com - March 16 at 8:01 AM
	IMNM Oct 2024 25.000 put finance.yahoo.com - March 16 at 8:01 AM
	IMNM Oct 2024 45.000 call finance.yahoo.com - March 16 at 7:48 AM
	Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors businesswire.com - February 20 at 8:15 AM
	StockWatch: Lilly’s Weighty Q4 Results Impress Investors, Analysts genengnews.com - February 11 at 11:32 PM
	Advaxis Executes Strategic Unregistered Equity Sales msn.com - February 10 at 8:13 AM
	Immunome leaps on news of Phase III asset buy thepharmaletter.com - February 7 at 12:57 PM
	Advaxis Announces Definitive Agreement with Ayala Pharmaceuticals msn.com - February 7 at 7:56 AM
	Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors msn.com - February 6 at 9:03 AM
	Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals finance.yahoo.com - February 6 at 8:10 AM
	Ayala Pharmaceuticals Inc Ordinary Shares ADXS morningstar.com - November 24 at 7:40 AM
	Ayala Pharmaceuticals: Fiscal Q4 Earnings Snapshot sfgate.com - November 20 at 1:03 PM
	Ladenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS) msn.com - November 17 at 6:25 PM
	Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 finance.yahoo.com - October 23 at 7:30 AM
	Ayala Pharmaceuticals Announces Closing of Merger with Biosight finance.yahoo.com - October 19 at 8:13 AM
	Other OTC Pharmaceuticals - Canada statista.com - September 25 at 1:38 PM
	Other OTC Pharmaceuticals - Netherlands statista.com - September 25 at 1:26 AM
	Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com - August 10 at 4:46 PM
	Ayala Pharmaceuticals Inc (ADXS) investing.com - August 3 at 8:40 AM

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals

NASDAQ:ADXS

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Compare Stocks